Miradry Treatment for Focal Axillary Hyperhidrosis

Inclusion Criteria

• •This study will recruit patients diagnosed with focal hyperhidrosis with a known diagnosis of primarily axillary localization.
• •We will only enroll patients available for both treatment visits. Availability for follow-up visit is optional.
• •Only patients between the ages of 18 and 29 years when the first HHIQ is administered will be eligible.
• •The upper age limit was so determined because patients over 29 years often present with psychopathology which is far more recalcitrant to correction of any kind regardless of effectiveness because of the duration of the condition.
• •The lower age limit was so determined because 18 years and up are the ages for which the miraDry ® procedure has been approved for use by the FDA.
• •All participants will be screened using the Hyperhidrosis Disease Severity Scale (HDSS).
• •Only patients reporting their condition as a 3 out of 4 or higher on the HDSS will be eligible for study because preliminary data suggests effective detection of psychological changes only at higher reported levels of sweating severity.
• •A patient's previous non-invasive treatment course, including but not limited to prescription of psychiatric medication and topical therapies, will not justify exclusion from this study.